chrX-77682608-T-C
Variant summary
Our verdict is Benign. Variant got -19 ACMG points: 1P and 20B. PP2BP4_StrongBP6_Very_StrongBS1BS2
The ENST00000373344.11(ATRX):āc.2648A>Gā(p.Gln883Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000156 in 1,208,866 control chromosomes in the GnomAD database, including 1 homozygotes. There are 108 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 14/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q883K) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000373344.11 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATRX | NM_000489.6 | c.2648A>G | p.Gln883Arg | missense_variant | 9/35 | ENST00000373344.11 | NP_000480.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATRX | ENST00000373344.11 | c.2648A>G | p.Gln883Arg | missense_variant | 9/35 | 1 | NM_000489.6 | ENSP00000362441 | P3 |
Frequencies
GnomAD3 genomes AF: 0.0000806 AC: 9AN: 111690Hom.: 0 Cov.: 22 AF XY: 0.000148 AC XY: 5AN XY: 33894
GnomAD3 exomes AF: 0.000291 AC: 53AN: 181928Hom.: 0 AF XY: 0.000553 AC XY: 37AN XY: 66864
GnomAD4 exome AF: 0.000164 AC: 180AN: 1097121Hom.: 1 Cov.: 34 AF XY: 0.000284 AC XY: 103AN XY: 362797
GnomAD4 genome AF: 0.0000805 AC: 9AN: 111745Hom.: 0 Cov.: 22 AF XY: 0.000147 AC XY: 5AN XY: 33959
ClinVar
Submissions by phenotype
Alpha thalassemia-X-linked intellectual disability syndrome Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 12, 2024 | - - |
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 24, 2020 | - - |
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2017 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 12, 2020 | - - |
not specified Other:1
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at